STOCK TITAN
  1. Home
  2. News
  3. RHHBY

Roche Holding AG - RHHBY STOCK NEWS

Welcome to our dedicated news page for Roche Holding (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roche Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roche Holding's position in the market.

News
Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing
Rhea-AI Summary
Remix Therapeutics (Remix) (SIX: RO, ROG; OTCQX: RHHBY) has announced a collaboration and license agreement with Roche for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform. Remix will receive an upfront payment of $30 million and is eligible to receive up to $12 million in near-term milestone payments, as well as preclinical, clinical, commercial and sales milestones of up to $1 billion and tiered royalties. Roche will have exclusive rights to specific targets, and Remix will conduct discovery and preclinical activities with Roche, while Roche will be responsible for development and commercialization of any resulting products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
News
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to acquire select parts of LumiraDx group (NASDAQ GS: LMDX) for a purchase price of USD 295 million, with an additional payment of up to USD 55 million. The acquisition will complement Roche’s centralised diagnostics portfolio across various disease areas, offering more affordable and accessible testing to patients worldwide. The transaction is expected to be finalized by mid-2024, subject to certain conditions including antitrust and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. FDA has accepted the company’s sBLA for Xolair for the reduction of allergic reactions from food exposure. The drug showed positive interim analysis results from the phase III OUtMATCH study, significantly increasing the amount of peanut, milk, egg, and cashew it took to cause an allergic reaction. The FDA is expected to make a decision on approval in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
clinical trial
News
Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
Rhea-AI Summary
Roche (ROTKREUZ) announces healthcare professionals' excellent ratings for navify Tumor Board, POC Operations, and Lab Operations in an independent report by KLAS® Research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
News
Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices
Rhea-AI Summary
Roche (RO, ROG; RHHBY) ranks third among the most sustainable healthcare companies in the Dow Jones Sustainability Indices. This marks the 15th year of Roche's leading ranking, emphasizing its commitment to sustainability in innovation management, access to healthcare, greenhouse gas emissions, water management, resource efficiency, circularity, labour practice indicators, and human rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
News
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) presented new data from its CD20xCD3 T-cell engaging bispecific antibody programme at the 65th ASH Annual Meeting, showing durable responses in heavily pre-treated lymphoma patients. Longer-term follow-ups of Columvi and Lunsumio studies demonstrated sustained remissions, reinforcing the potential of combination regimens in earlier treatment settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
News
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
Rhea-AI Summary
Genentech, a member of the Roche Group (RO, ROG; RHHBY), presented new data at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, showcasing the durable responses in heavily pre-treated lymphoma patients with their CD20xCD3 T-cell engaging bispecific antibody program, Columvi and Lunsumio. The data also reinforced the potential of combination regimens in earlier treatment settings, supporting ongoing Phase III studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
News
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the positive results of the Phase III HAVEN 7 study at the ASH 2023, reinforcing the efficacy and safety of Hemlibra in infants with severe haemophilia A without factor VIII inhibitors. The study showed meaningful bleed control in babies up to 12 months of age, with no spontaneous bleeds requiring treatment and no new safety signals observed. Hemlibra was well tolerated and exhibited consistent safety results. The study reflects Roche's commitment to advancing treatment standards for haemophilia A patients, providing additional confidence in the efficacy and safety profile of Hemlibra for babies with severe haemophilia A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
Rhea-AI Summary
Genentech, a member of the Roche Group (RO, ROG; RHHBY), announced the Phase III HAVEN 7 study results at ASH 2023, reinforcing the efficacy and safety of Hemlibra in infants with severe hemophilia A without factor VIII inhibitors. The study showed meaningful bleed control in babies up to 12 months of age and was well tolerated, with no new safety signals. Hemlibra provides a flexible and subcutaneous treatment option for babies, improving long-term outcomes and reducing the risk of intracranial hemorrhage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Rhea-AI Summary
Roche (RO, ROG, RHHBY) presented positive results from the Phase III INAVO120 study, showing inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone for people with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The inavolisib combination reduced the risk of disease worsening or death by 57% and showed clinically meaningful increases in objective response rate, duration of response, and clinical benefit rate. Overall survival data were immature, but a clear positive trend was observed. The inavolisib combination was well tolerated, with no new safety signals observed. Inavolisib is currently being investigated in three Phase III clinical studies in people with PIK3CA-mutated locally advanced or metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
Stock RHHBY logo
Roche Holding AG

OTC:RHHBY

RHHBY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

RHHBY Stock Data

199.10B
727.48M
0.15%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Basel